1. Volume 121, Issue 12, Pages 2473-2481 (December 2014)
A Randomized Clinical Trial of Intravitreal Bevacizumab versus Intravitreal Dexamethasone for Diabetic Macular Edema 
Mark C. Gillies, MBBS, PhD, Lyndell L. Lim, MBBS, Anna Campain, PhD, Godfrey J. Quin, MBChB, PhD, Wedad Salem, MB BS, MPH, Ji Li, MB BS, Stephanie Goodwin, BAppSc (Orthoptics) (Hons), Christine Aroney, MBBS, Ian L. McAllister, MBBS, Samantha Fraser-Bell, MBBS, PhD 
Ophthalmology 
Volume 121, Issue 12, Pages (December 2014)
DOI: /j.ophtha
Copyright © 2014 American Academy of Ophthalmology Terms and Conditions

2. Figure 1
Diagram showing the progression of patients through the study. DEX = dexamethasone; LOCF = last observation carried forward.
Ophthalmology  , DOI: ( /j.ophtha )
Copyright © 2014 American Academy of Ophthalmology Terms and Conditions

3. Figure 2 Mean best-corrected visual acuity by treatment type.
Ophthalmology  , DOI: ( /j.ophtha )
Copyright © 2014 American Academy of Ophthalmology Terms and Conditions

4. Figure 3
Bar graph showing the distribution of number of treatments given by treatment group for patients completing the 12-month follow-up visit. DEX = dexamethasone.
Ophthalmology  , DOI: ( /j.ophtha )
Copyright © 2014 American Academy of Ophthalmology Terms and Conditions

5. Figure 4
Graph showing the mean central macular thickness by treatment type for each month of follow-up. DEX = dexamethasone.
Ophthalmology  , DOI: ( /j.ophtha )
Copyright © 2014 American Academy of Ophthalmology Terms and Conditions